Clinical Trial Detail

NCT ID NCT01588431
Title Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ahmad Wehbe
Indications

head and neck cancer

Therapies

Cetuximab + Cisplatin + Docetaxel

Bevacizumab

Age Groups: adult

No variant requirements are available.